Compare Orion Office REIT Inc (ONL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Orion Office REIT Inc trades at $2.19 (market cap $125.50M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 1016.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ONL | VRTX | |
|---|---|---|
Market Cap | $125.50M | $127.55B |
Volume | 303,276 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $557.96 |
52-Week Low | $1.93 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $542.43M | $121.68B |
Dividend Yield | 3.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.27, down 2.58% today, with a bearish technical signal from moving averages but bullish oscillators. The company shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Analyst consensus is split 50/50 buy/hold, while recent news highlights strategic portfolio repositioning and Q2 2026 earnings beat.
Outlook remains challenged by negative profitability and high debt levels, though low P/B of 0.2 suggests deep value. Key risks include office sector headwinds and cash flow volatility. Investment appeal hinges on successful execution of turnaround strategy amid weak fundamental trends.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
